Dr Reddy's gains on launch of Sumatriptan injection in US
Published: 26th February 2014 11:19 AM
Last Updated: 26th February 2014 11:19 AM
Laboratories shares gainedon Wednesday after it launched
Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL, for
Subcutaneous Use, a therapeutic equivalent generic version of
IMITREX STATdose PenÂ® (sumatriptan succinate) 6 mg/0.5
mL in the US market on Feb. 25, 2014, following the approval by the
United States Food & Drug Administration (USFDA).
The IMITREX STATdose PenÂ®
(sumatriptan succinate) brand and generic combined had U.S. sales
of approximately $169 million MAT for the most recent twelve months
ending in December 2013 according to IMS Health.
Shares of the company are trading at Rs 2,800.00, up Rs 26.1, or
0.94% at the Bombay Stock Exchange (BSE) on Wednesday at 10:14
a.m.The scrip has touched an intra-day high of Rs 2,823.00 and low
of Rs 2,785.90. The total volume of shares traded at the BSE is
6,480.In the earlier session, the shares fell 0.76%, or Rs 21.25,
at Rs 2,773.90.Currently, the stock is trading down 0.53% from its
52-week high of Rs 2,815.00 and above 62.74% over the 52-week low
of Rs 1,720.50.